{"blog": [], "keywords": [{"value": "Valeant Pharmaceuticals International Inc", "name": "organizations", "rank": "1", "is_major": "Y"}, {"value": "Pearson, John Michael (1959- )", "name": "persons", "rank": "2", "is_major": "Y"}, {"value": "Schiller, Howard B", "name": "persons", "rank": "3", "is_major": "Y"}, {"value": "Ackman, William A", "name": "persons", "rank": "4", "is_major": "Y"}, {"value": "Appointments and Executive Changes", "name": "subject", "rank": "5", "is_major": "N"}, {"value": "Shareholder Rights and Activism", "name": "subject", "rank": "6", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/03/22/business/valeant-ackman-pearson-earnings.html", "document_type": "article", "byline": {"person": [{"lastname": "THOMAS", "firstname": "Katie", "role": "reported", "organization": "", "rank": 1}, {"lastname": "POLLACK", "firstname": "Andrew", "role": "reported", "organization": "", "rank": 2}], "original": "By KATIE THOMAS and ANDREW POLLACK"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/03/22/business/22valeant2/22valeant2-thumbWide.jpg", "legacy": {"wide": "images/2016/03/22/business/22valeant2/22valeant2-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/03/22/business/22valeant2/22valeant2-articleLarge.jpg", "legacy": {"xlarge": "images/2016/03/22/business/22valeant2/22valeant2-articleLarge.jpg", "xlargeheight": "368", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 368}, {"url": "images/2016/03/22/business/22valeant2/22valeant2-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/03/22/business/22valeant2/22valeant2-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "1312", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "Valeant\u2019s chief will step down, one of many changes made by the drug maker, which faces a growing list of questions from investors and regulators.", "pub_date": "2016-03-22T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "Shake-Up at Valeant Signals End of an Era", "main": "A Shake-Up at Valeant Signals the End of an Era"}, "print_page": "1", "snippet": "Valeant\u2019s chief will step down, one of many changes made by the drug maker, which faces a growing list of questions from investors and regulators.", "_id": "56eff71838f0d81c2692dd29", "slideshow_credits": null, "abstract": "Valeant Pharmaceuticals announces major changes to its leadership, including resignations of chief executive J Michael Pearson and board member Howard B Schiller; also says it will restate its earnings and put activist shareholder William A Ackman on its board; shake-up offers signal firm is rethinking its performance-based environment."}